Healthcare News 7

• 100% Survival Rates?? I Don't think So.
• A boost for the generic
• A cost saving?
• A coup for Novartis
• A dangerous spiral
• A good addition if holds up in Phase 3 studies
• A good new tool
• A major problem
• A new era for the FDA
• A new safe and sustaining adjunct to the treatment of neovascular AMD
• A novel therapeutic avenue?
• A potent analgesic without addiction potential?
• A potential breakthrough
• A Promising New Therapy For a Disease on the Increase
• A TRUE BREAKTHROUGH IN MEDICINE IF RESULTS ARE CONFIRMED
• A welcome addition
• A welcome improvement of the dynamic hip screw
• Absolutely! The Million Dollar Q though is How?
• Acadia’s ACP104: A Major Hurdle to Clear
• Actemra - my kingdom for some data
• Actemra in RA - and here's data
• Active agent in a narrow market
• Active Pharmaceutical Ingredients Producers Follow the Move to China
• Active Pharmaceutical Ingredients Producers Follow the Move to China
• Actonel ® (risedronate sodium) Procter & Gamble (NYSE: PG) Sanofi-aventis Paris (EURONEXT: SAN) New York (NYSE: SNY).
• Actonel 75 - the glass 1/2 full?
• Actonel bi-monthly - less is more
• Actonel is a threat ti Boniva and Fosamax?
• ADC for NHL: promising animal data
• Adherence is already a problem, plan design that just makes it worse is bad business
• Advanced Medical Optic's Complete MoisturePlus Contact Lens Solution Recalled Due to Increased Risk of a Sight-Threatening Infection
• Affordable Healthcare in the United States- NOT :Borders are no barrier to affordable healthcare | www.latimes.com
• Agonist/antagonist: What will this mean for the general public??
• Alcon with Alegretto can satisfy LASIK surgeons
• Alkermes’s ALKS 29: Another Shot at Alcoholism
• ALKS 29 could boost the bottom line!
• All the rage!
• All well and good BUT.....
• Already known
• Alternative treatment to depression: where we go from here?
• Alzheimer Drug patch analysis
• Alzheimer's drug patch could change quality of life
• Alzheimer's Drug Patch Important Advance
• AMA Fight Over Retail Clinics Might Slow Growth but Arguments are Not Strong
• AMO makes Bid for Bausch and Lomb
• AMO Seeks B & L
• AMO will Push Hard to Increase INTRALASE Penetration in the LASIK Market in 2008 and Beyond
• AMO's Acquisition of Baush & Lomb: A New Force in Ophthalmology?
• AMP Final Rule: PBM Impact
• AMP: Impact on Retail Pharmacy
• An antiinflammatory with few side effect
• An Excellent Way for Insurers To Cut Costs, Which Should Be Implemented On a Wider Basis
• An Ominous Trend
• Analysis of Common Causes of Diarrhea
• Anesiva versus Genzyme in knee OA
• Angiogenesis (Growth factors) for peripheral arterial disease
• Another arrow in the quiver to treat OSA
• Another attempt to sway from Aricept
• Another Biaxin- Why?
• Another flaw in our system
• Another surprise break through in NSCLC - NOT
• ANti VGEF THERAPIES ARE NOT JUST FOR MACULAR DEGENERATION
• Antidepressant Backlash Can Be Depressing for Patients, Psychiatrists and Big Pharma
• Antidepressant medications are not for everyone and these medications are not all the same
• Antidepressants and Pregnancy: Difficult Choices
• Anti-IL-5 receptor antibody treatment in Phase I study
• Anti-Integrins: A New Potential Treatment Modality for Wet (Neovascular) AMD?
• Antiplatlet-yes:anticoagulant-no
• Anti-Vaccine Hysteria or Real concerns???
• Apple (Aapl) IPhone: A Major Step Forward in Information Access for Physicians
• Apples to Oranges
• Approaches to the 'polypill" for hypertension
• Approval of Prestige is good news for the industry
• are there confounding variables?
• Aripiprazole sNDA expected to have fast approval for Bi Polar I
• Aripiprazole: jockeying for position
• AS AN ORGANIZATION THE FDA MAY GRIND SLOWLY BUT THEY ALSO GRIND RATHER FINELY
• As the world of radiology moves towards being 100% digital the need for improved computer interface systems has never been higher
• Aspect Medical Systems (ASPM) vs. CNS Response (CNSO.OB) - Zero in on Depression?
• Avandia/Actos and Phen/Fen: Overlapping Fates
• Avandia---wait for RECORD
• Axitinib: Is it better than Traceva???
• Bad news for Depomed
• Bariatric surgery is a useful adjunct in the management of obese diabetics
• Be Skeptical of Anti-Vaccine Press
• Belinostat: Need to be combined with other agents
• Benefits of autologous chondrocyte implantation versus potential risks
• Better Quality Today Nets These Doctors More Pay!
• Bifocal Lasik is Just Monovision in Disguise!
• Bifocal Lasik or is it Really Monovision
• Bifocal LASIK Surgery--Stroke of Genius or Variation on an Old Theme?
• Big Pharma's Thuggish Intimidation Tactics Will Fail
• BiovaxID: Nothing to write home about
• Black Box warnings are not a solution for inappropriate prescribing.
• BMS’ Abilify: Seeking a Slice of the Antidepressant Market
• Bonuses or Incentives for Healthy Lifestyle Choices Make Sense but are Only One Piece of the Puzzle
• Cartilage repair/restoration has viable results in well choosen patients
• Cell Transfer Device for Corneal Wound Healing
• CellCept may work for lupus nephritis
• Cephalon (Ceph) Takes Another Swipe at Daytime Drowsiness
• Cephalon BUNK
• Cephalon’s Nuvigil™ is Approved, but Don’t Hold Your Breath!
• Cepheid's Value
• Cethromycin shows efficacy and safety in CAP study
• Chantix is a concept now, at Phase III all the investors will want to be in the know.
• Chantix: it is not just "smoke and mirrors"
• Clinical impact of a predictable bone regenration paste
• CMS Begins Implementing Medicare Advantage Plan Marketing Changes
• Cobalis PreHistin - another one bites the dust
• Collegium Pharmaceutical Attempts to Create a Better Oxycontin
• Combination modalities significantly improve bronchoscopic results
• Comments
• Comments on the AWP Decision
• Confusing Report of Alternative to CPAP
• Convenient yet Safe should rule.
• Corneal Stem Cells: A Cure All for Eye Disease?
• Cost an issue
• COST EFFECTIVENESS OF AVASTIN MAY BE HUGE ….VERDICT STILL OUT ON ITS SAFETY AND EFFECTIVENESS FOR MACULAR DEGENERATION
• Covering Onychomycosis
• Cutting MD pay does NOT improve quality of care!
• Cyberknife is a part of radiation oncology future
• Cytos fails in AD
• Decreasing PSA is not enough of an answer
• Define Blockbuster?
• DELIVERY SYSTEM OF NEW MACULAR DEGENERATION DRUGS MAY BECOME VERY IMPORTANT
• Depression and Brain Effects: "Pseudodementia" May Not be "Pseudo"
• Depression Linked to Dementia
• Dermlex Launch
• Developing Drugs with Less ‘Isomeric Ballast’: For Clinical Value or Commercial Profit?
• Device attacks ischemic stroke without mercy
• Disease Management for Diabetes: What Are Big Companies Missing?
• Do not expect improvement when things are already being done
• Docs just got to prescribe otherwise why recognize a problem? Let's not throw out the baby with the bath water!
• Does have downsides
• Does this mean that fibromyalgia is now considered a real disease?
• Don't forget the lyphatics, they are the hydraulics of our body...
• Don't hold your breath !!!
• Drug Wholesaler Buybacks = Risk Aversion?
• Drugs have proven value
• DTC in the long run may not lead to a good doctor- patient relationship
• DTC marketing should be stopped
• Dying PDT
• EBUS but not EBN may prove to be a useful procedure in the future to evaluate lung lesions
• effective treatment?
• Efficacy of fexofenadine
• Efficacy will depend on the lack of resistance formation.
• EHR's Are What Are Made of Them
• Eliminating Pharmaceutical detailing: Throwing at the baby with the bath water.
• embracing progress
• Employer's initiatives to introduce health coaching: a debate between remote type vs face-to-face coaching
• Encouraging news for a novel theraputic approach
• Equal Treatment
• Erythropoietin (Epo) receptor stimulator? Cool!!
• Essential? You bet!
• Evista is a good option for use in Breast Cancer
• Exciting Collaboration between Surmodics (SRDX) and Merck (MRK)
• Exelon skin patch is a new treatment for Alzhiemer's disease-Novartis wins the US food and drug administration approval
• exforge true observance improvement associating two efficient blockbusters in the treatment of high blood pressure
• Factors II (Thrombin) and X are not the only places to halt the coagulation cascade
• Fancy Delivery System Offers No Additional Value
• Favid : Feasibility NOT efficacy
• FDA "Bifocal LASIK approval" not truly for bifocal vision.
• FDA 1, Supplement Industry 0: Fair and Balanced
• FDA Advisory Leads to A Disturbing Trend: Patients Undiagnosed and Untreated
• FDA will accept the advisory panel's decision, though it is not required to do so. Evista, an osteoporosis drug is likely to win the approval is seeks.
• Fighting Back Against The Third Party Practice of Medicine
• Finally a meaningful P4P
• FIRE STAR™ Rx PTCA Dilatation Catheter - an incremental improvement, not disruptive technology
• FLAP over asthma.
• Florida Medicaid Reform - Is it A Concept for Other States
• For all You Do, This Chip's for You!
• For real or for show?
• Frequency of bupropion use for the treatment of depression: a research report
• Galvus is way behind the eight ball in diabetes care.
• Gardasil is effective and widely accepted
• Generic Epilepsy Drugs: Is the Price Too High for Less Expensive Drugs?
• Generics will prevail despite the efforts of Big Pharma
• Geron (Gern) Telomerase Activators and Reversing Aging - Revolutionary or Too Good to Be True?
• Give me a break!!!
• GlaxoSmithKline (GSK) Creates a Well-Oiled Machine
• Golimumab in RA - better than Remicade
• Good drug: to be used better
• Good experience with pcm
• good for IM's limited use for cardiologists
• Good for the consumer-the death knell for the local pharmacy
• Good idea, but a high bar to cross
• Good news for generic manufacturers!
• Good News for Physicians and Patients, Bad News for Pharmaceutical Companies
• Good news for velcade, but an imperfect trial
• Good reminder
• Great confusion
• Great if results hold up
• Great product, but not for treatment planning
• Health Savings Plans are not the Panacea
• Healthways again shines in the commercial market, Medicare continues as a Problem
• help for the biologics failures? with RA
• hope for brain cancer patients?
• How generics divert income from innovators
• How important is Healthcare now and in the future.
• Hybrid Record Systems - Allow Phased Deployment, Risk of Prolonged Implementation
• Hybrid records a reality - but create some challenges
• I am not surprised but..........
• I Am Tired of Studies Like This
• I can hardly wait to see the advertising campaign for this one!
• I hope there is a plan B......
• I would love it
• If cheaper in the US -a real cost savings- but needs to be used appropriately
• I'll have my steak medium-rare...and, yes, maybe I'll prescribe your product.
• I'm Impressed
• I'm sure it will be as good as every other cancer vaccine.....
• Imaging technique may offer early diagnosis, but does not offer hope of improving therapy
• Impact of MR guided breast biopsies potentially of massive importance
• Impact of restrictions on gifts to MD's on prescribing patterns
• Improved interventional pulmonology is good for patients and payors
• Improving Quality Today Nets These Doctors More Pay!
• in diabetes treatment, a drug's mechanism of action may be just as important as the endpoint
• in diabetes treatment, the process may be just as important as the endpoint
• In Health Care, You Get What Your Pay for...Right?
• In the Long Run Sales of Alli Are Sure to Disappoint
• Incorporation of physician extenders and implementation of electronic data systems in hospitals to ease burden on interns and residents
• Industry Reactions to AMP
• Influence of advertising on pharmaceutical sales
• Interesting New Test But Currently No Clinical Indication
• Intersting concept but still too preliminary
• Intersting New Hyperlipidemia Drug Still Has a Long Way To Go
• Intervention techniques to improve chronic disease management quality can yield better quality care delivery.
• INTUNIV - another arrow in the quiver is welcome
• INTUNIV extended release tablets for the treatment of ADHD
• INTUNIV SHOULD CAPTURE AND RETAIN LIMITED MARKET SHARE
• INTUNIV: The market-share pie (a la mode) and unjust desserts!
• Intuniv: Potentially Good Addition but a Small-Scale Segment of the ADHD Market
• INVEGA - Two Innovations in One Pill
• Invega is Ready for the EU, But is the EU Ready for Invega?!
• Is it better than either with a diuretic?
• Is it Real? Maybe!!
• Is Suicide Painless? Why Zimulti/Rimonabant Has a Second Chance.
• Is the market alone responsible for Bexxar and Zevalin being underused?
• Isotechnika Inc. gains enough patients for Phase III clinicals, good news, required news.
• It's about time
• It's About Time
• It's Only Taken About One Hundred Years
• Ixabepilone for recurrent breast cancer: Efficacy is not proven yet
• Janssen’s INVEGA: A Better Risperdal?
• Johnson & Johnson(JNJ) Proves its "Staying Power" with New Sex Drug
• Keep holding your breath
• Key Determinant which treatment works best for which particular patient
• King Pharma's New Thrombin Delivery Kit Has a Good Nose
• Large scale electronic medical record implementation
• Leaving the elderly and many doctors out in the cold.
• Lessons learned from practioners
• Let the Marketplace decide
• Let's not be hasty!
• Likely to get approved, but maybe for a targeted population
• LIKELY TO IMPROVE ADHERENCE
• Liver biopsy for psoriasis
• Long term data needed
• Long-term safety needed
• Lunesta's flying sllep moth
• Lyrica and fibromyalgia - I hope it works
• Lyrica and its efficacy in treating fibromyalgia
• Lyrica as an effective drug for managing chronic pain associated with Fibromyalgia
• Lyrica may soothe Pfizer's pain
• Lyrica used for treatment of fibromyalgia
• Lyrica’s Fibromyalgia Indication: A Good Break for Pfizer
• Mail order fallacy.
• Mail will grow, but independent pharmacies won't
• Major breakthrough!
• Managemnet and oversight issues
• Maraviroc will aid decrease HIV drug resistence
• Marketing Overview
• May be a coup, maybe not
• McDoc-in-the-box
• Medical Cost Control
• Medical Tourism's Holy Grail
• Medicare Advantage - Reimbursement Cuts Are On The Way
• Medicare cuts will result in quality cuts in the program for the elderly
• Medicare's Proposes Major Cuts in Physician Reimbursement
• Medications for obesity and FDA
• MedImmune offers renewed hope for targeted anti-IL-5 therapy for asthma
• Medtronic's Bryan disc has all the elements of success
• MERCI retrieval system is a step forward, but limitations for widespread use are substantial
• Metabasis Novel Product MB07811 May Be Limited By Side Effect Profile in Humans
• Milestone?? Yes but rather premature!
• Millennium & Velcade Redux
• Minute Clinics nothing more than an economic battle
• More Bad News for Sanafi Aventis’ Acomplia
• More of the same with a twist
• More power to the Cerner suite of software
• More questions than answers raised by this report
• MRE likely many years from true utility
• Multitalented?
• Needle sticks still a problem
• Nelarabine: Moderate efficacy but beware of neurotoxicity
• Nelarabine: Will It increase cure rates in front-line T-cell patients??
• Net benefit, though the margin of benefit may be slight.
• Neuropathic pain more common that thought of.
• 'New' (and expensive) doesn't necessarily equal better!
• New approach to AMD treatment
• New Drug for Osteoarthritis of Knee Could Have Great Promise
• New Medicaid payment rules could benefit brand drug manufacturers
• New Method Of Adult Stem Cell Growth Treats Cornea Disorders
• New novel therapy, but a long way to go
• New Oral Opioid Treatment for Chronic Pain
• New Stealth Missile??
• New? Not Really
• Nexavar is effective for Liver cancer and soon for many other solid tumors
• Next stop for ASA404
• No good news yet
• No news
• Noninferiority vs. Cost
• Non-stimulant treatment for ADHD - a new alternative
• Nonstimulant treatment of ADHD is a good idea but how effective is it?
• Not so quick
• Not without potential side effects
• Novel Approaches In Their Back Pocket, and In Others' Too
• Novel drug to increase hemoglobin
• novel pathway
• Nuvelo Pharmaceuticals Phase II trial of a Nematode derived anticoagulant for ACS
• Nuvigil may have major advantages compared to Provigil
• Ofatumumab in RA - Genentech can breath easier.
• Older diabetic medications are far from being adequate
• On The Move
• Once Daily Dosing About Patients--Not Just Patents
• Once daily Welbutrin XL represents a significant advance
• Oncologists Vote Their Pocketbook
• One Half of a Holy Grail?
• Only if it can beat Avastin front line....
• Opexa - Personalized medicine for Multiple Sclerosis
• Opinions should not be expressed before information is available
• Oral Toptecan: Not very exciting!!!
• Orthopedic procedures on the rise
• OSI-906: rationale and pre-clinical data make sense, but clinical data may not!!!
• Overworked Interns, "Holy Grays Anatomy!"
• Palliative treatment made quicker
• Paper Kills...So What are We Waiting For?
• Patients are happy- PBMs too
• PDE-5 class effect on Raynauds may provide evidence that SLx-2101 will work
• PDT MAY CONTINUE TO SERVE A ROLE IN THE TREATMENT OF WET MACULAR DEGENERATION
• Pedigree and Distributor Profits
• Pennsylvania Leads the Way in a New Freedom--from Hospital Infections
• PercSys Accordion(R) Stone Management Device is more effective
• Perhaps a welcome addition
• Perhaps Poisoning is Not Necessary....? Diagnostics may save the day for some.
• Personal Health Records--a call to action
• Pfizer and Wyeth need better wholesaler monitoring
• Pfizer doubts RFID
• Pfizer on a come back: Fast Track Review for a Drug used in 5 Million Worldwide already
• Pfizer’s Lyrica Wins the Race
• PHAKIC IOLS ARE NOT DEAD
• Pharmaceutical advertising increases patient/physician communication.
• Pharmaceutical corporate behavior
• Pharmacuetical Companies and overcharging
• Phase 2 study showing that a 1mg treatment with Adlea(TM) effective for 12 week persistant pain in OA patients
• Physicians Are Furious
• Pill splitting
• pill splitting is not always a bargain
• Pill Splitting: Hated By Drug Companies, Loved By Patients
• Pitfalls in trial design
• Pixantrone : Quite Promising
• Point of Care
• Poor study -poor results
• Potential risks of autologous chondrocyte implantation and alternative techniques
• Potential viable treatment for chemo induced peripheral neuropathy
• Preliminary? Here is Real Preliminary but VERY Interesting
• Probably not so significant yet
• Pseudo-EEG testing
• Push and Pull: Smart Marketing
• Race and its Impact on the Care Provided
• Real Value for Alcon in Allegretto
• reality check
• Reclast, a great drug, but who is going to pay for it?
• Reduced healthcare costs or fatter insurance company profits?
• Relativity
• remember olestera? (anal leaking)
• Residents - Worked Like Rented Mules
• resveratrol has many actions that might account for its benefits
• Retail Clinics - Healthcare in Evolution
• Retail clinics created by doctors
• Retail Clinics: Unstoppable and Harbinger of a Broader Trend
• Retinol and Aged Skin
• Review of INTUNIV Extended Release for treatment of ADHD:
• Rimonabant - the FDA gets it wrong.......Again
• Rimonabant psychiatric "side effects" need to be viewed in terms of any existing psychopathology in patients for whom it is prescribed
• Roche/BioCryst in Psoriasis
• Roche/BioCryst psoriasis trial design
• Roches balances safety versus efficacy
• Roche's market share will go up .
• Rotarix may gain approval, but when and does it matter in the near term?
• Rx to OTC
• Rx: the Mediterranean Diet: But for Which Conditions?
• Safety Concerns Trump Public Health Benefit in the Eyes of the FDA Cardiorenal Panel
• Safety issue of Endeavor
• Sales Will Be Good Intially, Then Fall Off
• Say Goodbye to AWP
• Sculptra: proceed with caution
• Self expanding stents: the third generation
• Serving the Public Trust
• Sex Pill for Men Analysis
• SGLT inhibitor treatment of type 2 diabetes
• Shire (SHPGY) Expands Its ADHD Repertoire with a Promising Non-Stimulant
• Shire’s Intuniv™ for ADHD: Old Drug, Same Use
• Shocking? Not!!!!
• Simplifying DVT prophylaxis
• Sleep Apnea device good for some not for others
• Small But Interesting Study on New Anti-Skin Aging Drug
• Small delay for first CCR5 antagonsit
• SMOKING INCREASES RISK OF BLINDNESS DUE TO MACULAR DEGENERATION
• So Much for PF-3512676
• Something stinks around here!
• Something that works, but cost and the MORAL MAJORITY will interfere
• Specific Immunotherapy for NHL: Data is too preliminary
• Standard of Care? They Already are the Standard of Care!
• Strattice™ Opens up the Cosmetic Market
• Stryker: Implications of newly approved hip resurfacing implant
• Study of Electronic Health Records Looking at Wrong Factors
• Surgeons need to Protect Themselves and Their Patients
• Symlin—Lot’s of poken’ for a drug that’s not smoken’
• Synvisc - A single shot to the knee
• Takeda's TAK-491 for Treatment of Hypertension remains a hopeful.
• Th
• The (permanent) separation of pharma and academic medicine
• The annual Medicare Cliffhanger.
• The Answer is Still to be Determined
• The arrival of this blockbuster is delayed!
• the avandia saga
• The future???
• The Jury is Still Out on the Relative Value of Cepahalon's NUVIGIL(TM)
• The key to health care future.
• The next wave of AMD drugs? It's too early to say...
• The Real Deal?
• The right initiative
• The Solution is Socialized Medicine
• The worst yet to come
• These Cards are Smart...So You Don't Always Have to Be
• These clinics, if done correctly, could be a great extension of physician practices.
• This one may hurt.
• This one may hurt.
• Thymitaq in Hepatocellular Carcinoma
• To Echo or not to Echo: that is the Question!
• Too good to be true
• Too Good to be true for an agent with administration problems and side effects
• Too much hype in a crowded market
• Trail design appears to be solid for GVAX
• Tremendous savings in time and Efficiency for Device Clinics and Patients
• Trying to find a niche
• Typical deception
• U.S. Healthcare System Will Collapse Within The Next Ten Years
• Unclear if anything new
• Unexpected and disappointing negative outcomes for Gabapentin GR (TM)
• Unfortunate - but not shocking
• Use of Allied Health Providers in Medical Residency Training Programs
• Utility of MRE. Is it really as good as it sounds?
• Vaccine Has Potential To Be A Large Success
• VAD is nearly DEAD
• Vaniqa's effect on laser hair removal
• Velcade inching forawd in frontline treatment of Multiple Myeloma
• Velcade superior to VAD induction to transplant
• Very Controversial Way of Providing Care - Too Early to Predict Success or Failure
• Very Exciting Discovery
• Very exciting new lead in ADHD research
• Vitamin D DustUp Deserves No Damage...But Attention
• Vyvanse (NRP104) for ADHD: Can Shire really make this a blockbuster?
• Vyvanse, Concerta, and Adderall XR: How Will It Sort Out?
• Vyvanse-an important new medication but not the holy grail for ADHD
• Waiting on Pins and Needles???
• Walgreens expands in specialty
• We need a culture of safety, not more procedures and oversight
• We need new Diabetes medication- will this pass the safety test?
• Welcome addition
• Wellbutrin XL: Is There Still Room for Improvement?
• What do the results presented by SIRTRIS at the 6th Annual Metabolic Diseases Drug Discovery and Development World Summit mean for SIRTRIS?
• Whats good for the goose?
• Whats new in hypertension therapy - nothing , sort of
• What's the Big Deal
• When initial therapy needed.
• Where chemists cost too much, let nature do it
• Where's the "Beef?"
• Whither CombinatoRx?
• Who knows??
• Who Needs Another Extended Release Narcotic?
• Why AMP Matters:
• Why are Generic's Killing Innovative Branded Drugs
• Why elsewhere? Cost! "duh"
• Why internet medication? We need more control of PHARMACUTICALS
• Why many do not join the AMA
• Why rejected by the FDA panel
• Will it aid in QOL or survival?
• Will This Dog Hunt???
• Won't last long
• Wyeth’s Pristiq Delt a Blow On FDA request
• XOMA - antibody treatment for Diabetes
• Xyzal: Single Isomer Zyrtec, but still SEDATING. Yawn
• YEAHHH! We have another expensive vaccine!
• Yellow Journalism?
• Yes, ALT-2074 might be a practical add-on to standard diabetes-2 treatments. But there is a way to go.
• yet another anti IL5
• Yet another new Gram Positive Drug
• You May Not Like the Way He Says it But.......
• Your wallet.
• ZymoGenetics Signs Up Bayer to Drive Its U.S. and Foreign Thrombin Sales